Download PDF
CC BY-NC-ND 4.0 · Int Arch Otorhinolaryngol 2022; 26(03): e446-e452
DOI: 10.1055/s-0041-1740099
Original Research

Sinonasal Mucosal Melanoma: A Population-based Comparison of the EUROCARE and SEER Registries

David Temmermand 
1   Department of Otolaryngology – Head and Neck Surgery, Augusta University, Augusta, GA, United States
2   Department of Otolaryngology & Facial Plastic Surgery, Rowan University School of Osteopathic Medicine, Stratford, NJ, United States
,
Suat Kilic
3   Department of Otolaryngology – Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, NJ, United States
,
Mina Mikhael
3   Department of Otolaryngology – Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, NJ, United States
,
Jennifer Butler 
4   Medical College of Georgia, Augusta University, Augusta, GA, United States
,
Aykut A. Unsal
1   Department of Otolaryngology – Head and Neck Surgery, Augusta University, Augusta, GA, United States
2   Department of Otolaryngology & Facial Plastic Surgery, Rowan University School of Osteopathic Medicine, Stratford, NJ, United States
,
EUROCARE-5 Working Group › Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Introduction Sinonasal melanomas are rare tumors with no comparative survival studies between Europe and the US.

Objective To provide a population-based survival analysis between the two continents.

Methods The European Cancer Registry (EUROCARE) and the United States Surveillance, Epidemiology, and End Results (SEER) databases were queried to identify patients diagnosed with sinonasal melanoma between 2000 and 2007. Relative survival (RS) data were grouped by age, gender, geographic region, extent of disease, and treatment modality.

Results A total of 1,294 cases were identified between 2000 and 2007 (935 from EUROCARE-5 and 359 from SEER). Females were most commonly identified in Europe (56.4%) and in the US (54.9%). Patients over the age of 65 years comprised the greatest proportion of patients in Europe (70%) and in the US (71%). By region, Southern Europe had the highest 5-year RS (31.6%, 95% confidence interval [CI] = [21.3–42.5%]), and Eastern Europe the lowest (16.5%, [7.5–28.5%]). The aggregate European 5-year RS was 25.4% [21.8–29.1%] and the U.S. was (29.7%, [23.6–36%]).

Conclusions Although increasing in incidence, sinonasal melanomas remain rare. Women were more commonly affected. The most common age group was those older than 65 years, although age did not confer a prognostic value. The most common subsite was the nasal cavity followed by the maxillary sinus. Five-year RS was similar between continents with an inverse relationship between extent of disease and survival. The treatment of choice throughout Europe and the US remains primarily surgical.

Keywords

SEER program - melanoma - registries

Compliance with Ethical Standards

This article does not contain any studies with human participants or animals.


# Presented at the American Rhinologic Society Annual Meeting on September 9, 2017 in Chicago, IL.




Publication History

Received: 13 May 2020

Accepted: 07 August 2021

Article published online:
27 January 2022

© 2022. Fundação Otorrinolaringologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Mallone S, De Vries E, Guzzo M. et al; RARECARE WG. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur J Cancer 2012; 48 (08) 1167-1175
    CrossrefPubMedGoogle Scholar
  • 2 Stern SJ, Guillamondegui OM. Mucosal melanoma of the head and neck. Head Neck 1991; 13 (01) 22-27
    CrossrefPubMedGoogle Scholar
  • 3 Bishop KD, Olszewski AJ. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. Int J Cancer 2014; 134 (12) 2961-2971
    CrossrefPubMedGoogle Scholar
  • 4 De Angelis R, Sant M, Coleman MP. et al; EUROCARE-5 Working Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol 2014; 15 (01) 23-34
    CrossrefPubMedGoogle Scholar
  • 5 Coleman MP, Babb P, Damiecki P. et al. Cancer survival trends in England and Wales, 1971–1995: deprivation and NHS region. Stationery Office Books; 1999
    Google Scholar
  • 6 Patel SG, Prasad ML, Escrig M. et al. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002; 24 (03) 247-257
    CrossrefPubMedGoogle Scholar
  • 7 Thompson LD, Wieneke JA, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol 2003; 27 (05) 594-611
    CrossrefPubMedGoogle Scholar
  • 8 Van Dijk BA, Gatta G, Capocaccia R, Pierannunzio D, Strojan P, Licitra L. RARECARE Working Group. Rare cancers of the head and neck area in Europe. Eur J Cancer 2012; 48 (06) 783-796
    CrossrefPubMedGoogle Scholar
  • 9 Khan MN, Kanumuri VV, Raikundalia MD. et al. Sinonasal melanoma: survival and prognostic implications based on site of involvement. Paper presented at: International forum of allergy & rhinology 2014
    PubMedGoogle Scholar
  • 10 Samstein RM, Carvajal RD, Postow MA. et al. Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head Neck 2016; 38 (09) 1310-1317
    CrossrefPubMedGoogle Scholar
  • 11 Konuthula N, Khan MN, Parasher A. et al. The presentation and outcomes of mucosal melanoma in 695 patients. Int Forum Allergy Rhinol 2017; 7 (01) 99-105
    CrossrefPubMedGoogle Scholar
  • 12 Chang AE, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer 1998; 83 (08) 1664-1678
    CrossrefPubMedGoogle Scholar
  • 13 Williams MD. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Mucosal Melanomas. Head Neck Pathol 2017; 11 (01) 110-117
    CrossrefPubMedGoogle Scholar
  • 14 Castelnuovo P, Turri-Zanoni M, Battaglia P, Antognoni P, Bossi P, Locatelli D. Sinonasal malignancies of anterior skull base: histology-driven treatment strategies. Otolaryngol Clin North Am 2016; 49 (01) 183-200
    CrossrefPubMedGoogle Scholar
  • 15 Husain Q, Kanumuri VV, Svider PF. et al. Sinonasal adenoid cystic carcinoma: systematic review of survival and treatment strategies. Otolaryngol Head Neck Surg 2013; 148 (01) 29-39
    CrossrefPubMedGoogle Scholar
  • 16 Alves I, Berriel L, Alves R. et al. Sinonasal melanoma: A case report and literature review.
    Google Scholar
  • 17 Mikkelsen LH, Larsen AC, von Buchwald C, Drzewiecki KT, Prause JU, Heegaard S. Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey. APMIS 2016; 124 (06) 475-486
    CrossrefPubMedGoogle Scholar
  • 18 Marcus DM, Marcus RP, Prabhu RS. et al. Rising incidence of mucosal melanoma of the head and neck in the United States. J Skin Cancer 2012; 2012: 231693
    CrossrefPubMedGoogle Scholar
  • 19 Lombardi D, Bottazzoli M, Turri-Zanoni M. et al. Sinonasal mucosal melanoma: A 12-year experience of 58 cases. Head Neck 2016; 38 (Suppl. 01) E1737-E1745
    CrossrefPubMedGoogle Scholar
  • 20 Swegal W, Koyfman S, Scharpf J. et al. Endoscopic and open surgical approaches to locally advanced sinonasal melanoma: comparing the therapeutic benefits. JAMA Otolaryngol Head Neck Surg 2014; 140 (09) 840-845
    CrossrefPubMedGoogle Scholar
  • 21 Gal TJ, Silver N, Huang B. Demographics and treatment trends in sinonasal mucosal melanoma. Laryngoscope 2011; 121 (09) 2026-2033
    CrossrefPubMedGoogle Scholar
  • 22 Becker C, Kayser G, Pfeiffer J. Squamous cell cancer of the nasal cavity: New insights and implications for diagnosis and treatment. Head Neck 2016; 38 (Suppl. 01) E2112-E2117
    CrossrefPubMedGoogle Scholar
  • 23 Dubal PM, Bhojwani A, Patel TD. et al. Squamous cell carcinoma of the maxillary sinus: A population-based analysis. Laryngoscope 2016; 126 (02) 399-404
    CrossrefPubMedGoogle Scholar
  • 24 Rutherford MJ, Ironmonger L, Ormiston-Smith N. et al. Estimating the potential survival gains by eliminating socioeconomic and sex inequalities in stage at diagnosis of melanoma. Br J Cancer 2015; 112 (Suppl. 01) S116-S123
    CrossrefPubMedGoogle Scholar
  • 25 Primic-Zakelj M, Zadnik V, Zagar T. Is cancer epidemiology different in Western Europe to that in Eastern Europe?. Ann Oncol 2005; 16 (Suppl. 02) ii27-ii29
    CrossrefPubMedGoogle Scholar
  • 26 Xiao G, Cao Y, Qiu X, Wang W, Wang Y. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. BMC Cancer 2013; 13 (01) 226
    CrossrefPubMedGoogle Scholar